About Embla Medical

Sveinn Sölvason, President and CEO, comments:

“Sales in Q3 2026 were USD 250 million, representing 5% reported growth and 4% organic growth. Growth was driven by Prosthetics & Neuro Orthotics, with strong performance in EMEA, partially offset by softer results in Americas and APAC. Bracing & Supports delivered moderate growth, while Patient Care sales were flat in the quarter.

In Patient Care, sales performance has been below the expectations we set at the beginning of the year. Mainly as significant integration effort has slowed down our ability to drive growth in patient volumes in selected regions. We are encouraged by the progress we are making in a large part of our network of clinics, with significant work ongoing to enhance our performance across the whole Patient Care network.

EBITDA margin was strong in the quarter, or 22%, in line with Q3 2025, as disciplined cost control offset lower gross profit margin.

Based on our performance in the first nine months and our outlook for Q4 2026, we are narrowing our full-year guidance to approximately 5% organic sales growth (previously 5–7%) and an EBITDA margin of approximately 21% (previously 20–22%).”

A webcast can be followed by registering here.⁠

Please visit our Investor Relations section⁠ for further information.

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.